2010 Aggregate Disclosure and Spend Reporting Industry Study of compliance program experts Cegedim Dendrite today announced the outcomes of the 2010 Aggregate Spend and Disclosure Reporting Market Survey of compliance plan experts from Lifestyle Sciences companies. Cegedim Dendrite is the leading company of Customer Relationship Management , Regulatory Compliance, Data Optimization and Marketing solutions designed for the Life Sciences industry specifically. Cegedim Dendrite found that despite these needs, about 40 percent of respondents are still using manual reporting procedures; however, over half of these respondents plan to either outsource to a third-party or automate the process internally as more regulations are enacted.The existing study provides useful information for health practitioners and for potential interventions targeted at helping ladies obtain LCPUFA in their diet plan to ensure they are able to meet the needs of their infants.. Alkermes announces plans to advance ALKS 5461 phase 3 system for major depressive disorder Alkermes plc today announced that it provides successfully completed its End-of-Phase 2 interactions with the U.S. Meals and Drug Administration , and the company plans to advance ALKS 5461 into stage 3 advancement in early 2014. Alkermes can be developing ALKS 5461 for the treating patients with main depressive disorder who’ve inadequate response to regular therapies. The ongoing firm and the FDA agreed on important elements of the advancement program, including medical and preclinical requirements for the brand new Drug Application, the confirmatory study programs, the incorporation of innovative research designs that include the usage of sequential parallel comparison design , the primary endpoint and the statistical methodology.